Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 43712 results
Charles River acquires Galapagos' CRO services division
01 April 2014
Charles River Laboratories International (CRL) has completed the previously announced acquisition of the CRO services division of Galapagos (GLPGF), which includes both Argenta and BioFocus.
Contract Research & Services > Contract Research > News
Kyowa Hakko Kirin seeks Japanese approval for additional indication of NESP for anemia
01 April 2014
Kyowa Hakko Kirin has filed an application to Japan's Ministry of Health, Labour and Welfare (MHLW) seeking approval for additional indication of NESP Injection Plastic Syringe (NESP) for anemia with myelodysplastic syndrome.
Drug Research > Drug Delivery > News
NCCN gets $2.2m research funding to study enzalutamide in solid tumors
01 April 2014
The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has been awarded a $2.2m grant from Astellas Pharma and Medivation to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers.
Contract Research & Services > Contract Research > News
Eisai assigns worldwide rights of hematological cancer treatment Dacogen to Otsuka
01 April 2014 | By PBR Staff Writer
US subsidiary of Japan-based Eisai has entered into an agreement to sell and assign its rights to develop and market the DNA methylation inhibitor Dacogen (decitabine) in all countries excluding Mexico to Otsuka Pharmaceutical (Otsuka).
Contract Research & Services > Contract Services > News
EMIG welcomes DH funding for single approval system for clinical research
01 April 2014
EMIG has welcomed an announcement by the Department of Health to fund a Health Research Authority (HRA) business plan to deliver a single approval system for all health research studies in England.
Contract Research & Services > Contract Research > News
Palatin extends license option to bremelanotide in Europe
01 April 2014 | By PBR Staff Writer
US-based biopharmaceutical firm Palatin Technologies has granted an extension until 30 April 2014 to an existing option agreement with a potential commercial partner for an exclusive license to bremelanotide for female sexual dysfunction indications in selected European countries, including the European Union (EU).
Contract Research & Services > Contract Services > News
Sagent launches Adenosine injection in two preservative- free vial presentations
01 April 2014 | By PBR Staff Writer
US-based Sagent Pharmaceuticals has launched Adenosine Injection, USP, a pharmacologic stress agent, in two preservative- free vial presentations.
Drug Research > Drug Delivery > News
Lundbeck to enter into a partnership with Lieber Institute
01 April 2014
H. Lundbeck, together with a number of other companies, is now entering into a collaboration with the Lieber Institute, which has the world's largest collection of human brains from patients with psychiatric disorders.
Contract Research & Services > Contract Research > News
Takeda and Trianni sign licensing agreement for use of Trianni transgenic mouse platform
01 April 2014
Trianni and Takeda Pharmaceutical jointly have announced that they have entered into a license agreement for Takeda’s use of the Trianni Mouse, a monoclonal antibody discovery platform.
Contract Research & Services > Contract Services > News
US Supreme Court to hear Teva's appeal on Copaxone patent
01 April 2014 | By PBR Staff Writer
Israel-based Teva Pharmaceutical Industries has announced that the US Supreme Court has granted its Copaxone certiorari petition and will hear its appeal of a decision from the US Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the 808 patent).
Production & Manufacturing > Process & Production > News
Croma-Pharma signs distribution agreement with Hugel
01 April 2014
Croma-Pharma has announced the signing of a ten-year comprehensive and important distribution agreement with Hugel of Korea.
Production & Manufacturing > OTC > News
GSK uses Novozymes’ VELTIS half-life extension technology in its type 2 diabetes drug
01 April 2014
Novozymes Biopharma, a subsidiary of Novozymes, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline (GSK) in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.
Automation > IT & Software > News
FDA Advisory Committee recommends approval of Cubist’s Sivextro
01 April 2014
Cubist Pharmaceuticals has announced that the US Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist’s investigational antibiotic SIVEXTRO (tedizolid phosphate).
Regulatory Affairs > News
AstraZeneca, MRC enter into new drug discovery collaboration
01 April 2014 | By PBR Staff Writer
AstraZeneca has entered into a strategic collaboration with the UK Medical Research Council (MRC) to create a new center for early drug discovery in Cambridge, UK.
Drug Research > Drug Discovery & Development > News
Takeda's NDA for cell cultured influenza vaccine approved in Japan
01 April 2014 | By PBR Staff Writer
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical's new drug application (NDA) of Cell Cultured Influenza vaccine H5N1 'TAKEDA' 1mL (Cell Cultured Influenza vaccine (H5N1Strain)) and Cell Cultured Influenza vaccine (Prototype) 'TAKEDA' 1mL (Cell Cultured Influenza vaccine (Prototype)) for prevention of pandemic influenza.
Drug Research > Drug Delivery > News
136-150 of 43712 results